A Phase 1 Study of 4 Live, Recombinant Human Cytomegalovirus Towne/Toledo Chimera Vaccines in Cytomegalovirus-Seronegative Men

Journal of Infectious Diseases

Volumn 214, Issue 9, 2016, Pages 1341-1348

  Adler, Stuart P ^a   Manganello, Anne Marie ^a   Lee, Ronzo ^b   McVoy, Michael A ^b   Nixon, Daniel E ^c   Plotkin, Stanley ^d,e   Mocarski, Edward ^f   Cox, Josephine H ^g   Fast, Patricia E ^g   Nesterenko, Pavlo A ^h   Murray, Susan E ^h,i   Hill, Ann B ^h   Kemble, George ^b  

^a CMV Research Foundation Inc   (United States)

^b Department of Pediatrics ^*  (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e WISTAR INSTITUTE   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF PORTLAND   (United States)

Author keywords

cytomegalovirus; pregnancy; transplantation; vaccines

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYTOMEGALOVIRUS TOLEDO CHIMERA VACCINE; CYTOMEGALOVIRUS TOWN CHIMERA VACCINE; CYTOMEGALOVIRUS VACCINE; UNCLASSIFIED DRUG; LIVE VACCINE; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS VACCINE;

ABSENCE OF SIDE EFFECTS; ADULT; AFRICAN AMERICAN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CAUCASIAN; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMUNOGENICITY; MALE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEROCONVERSION; SIDE EFFECT; VACCINATION; VIRUS STRAIN; CHIMERA; CLINICAL TRIAL; CYTOMEGALOVIRUS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; CD4-POSITIVE T-LYMPHOCYTES; CHIMERA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; YOUNG ADULT;

EID: 84994718580     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw365     Document Type: Article

References (34)

1. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. Outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 1992; 326:663-7
2. Stratton KR, Durch J, Lawrence RS. Vaccines for the 21st century: a tool for decision making. Washington, DC: National Academy Press, 2000
3. Plotkin S. The history of vaccination against cytomegalovirus. Med Microbiol Immunol 2015; 204:247-54
4. Elek SD, Stern H. Development of a vaccine against mental retardation cased by cytomegalovirus infection in utero. Lancet 1974; 1:1-15
5. Plotkin SA, Furukawa T, Zygraich N, Huygelen C. Candidate cytomegalovirus strain for human vaccination. Infect Immun 1975; 12:521-7
6. Fleisher GR, Starr SE, Friedman HM, Plotkin SA. Vaccination of pediatric nurses with live attenuated cytomegalovirus. Am J Dis Child 1982; 136:294-6
7. Glazer JP, Friedman HM, Grossman RA, et al. Live cytomegalovirus vaccination of renal transplant candidates: a preliminary trial. Ann Intern Med 1979; 91:676-83
8. Just M, Buergin-Wolff A, Emoedi G, Hernandez R. Immunisation trials with live attenuated cytomegalovirus TOWNE 125. Infection 1975; 3:111-4
9. Pass RF, Burke RL. Development of cytomegalovirus vaccines: prospects for prevention of congenital CMV infection. Semin Pediatr Infect Dis 2002; 13:196-204
10. Plotkin SA. Vaccination against cytomegalovirus, the changeling demon. Pediatr Infect Dis J 1999; 18:313-6
11. Plotkin SA, Smiley ML, Friedman HM, et al. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1984; 1:528-30
12. Balfour HH Jr. Prevention of cytomegalovirus disease in renal allograft recipients. Scand J Infect Dis Suppl 1991; 80:88-93
13. Plotkin SA, Higgins R, Kurtz JB. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58:1176-8
14. Plotkin SA, Starr SE, Friedman HM, et al. Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant: a controlled trial. Ann Intern Med 1991; 114:525-31
15. Adler SP, Starr SE, Plotkin SA, et al. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 1995; 171:26-32
16. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 1989; 159:860-5
17. Prichard MN, Penfold ME, Duke GM, Spaete RR, Kemble GW. A review of genetic differences between limited and extensively passaged human cytomegalovirus strains. Rev Med Virol 2001; 11:191-200
18. Heineman TC, Schleiss M, Bernstein DI, et al. A phase 1 study of 4 live, recombinant human cytomegalovirus Towne/Toledo chimeric vaccines. J Infect Dis 2006; 193:1350-60
19. Kemble G, Duke G, Winter R, Spaete R. Defined large-scale alteration of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 1996; 70:2044-8
20. Penfold ME, Dairaghi DJ, Duke GM, et al. Cytomegalovirus encodes a potent alpha chemokine. Proc Natl Acad Sci U S A 1999; 96:9839-44
21. Wang JB, Adler SP, Hempfling S, et al. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 1996; 174:387-92
22. Cui X, Meza BP, Adler SP, McVoy MA. Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection. Vaccine 2008; 26:5760-6
23. Almanzar G, Schwaiger S, Jenewein B, et al. Long-term cytomegalovirus infection leads to significant changes in the composition of the CD8+ T-cell repertoire, which may be the basis for an imbalance in the cytokine production profile in elderly persons. J Virol 2005; 79:3675-83
24. Quinnan GV Jr, Delery MRA, Rook AH, et al. Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 1984; 101:478-83
25. Jacobson MA, Sinclair E, Bredt B, et al. Antigen-specific T cell responses induced by Towne cytomegalovirus (CMV) vaccine in CMV-seronegative vaccine recipients. J Clin Virol 2006; 35:332-7
26. Maecker HT, Rinfret A, D'Souza P, et al. Standardization of cytokine flow cytometry assays. BMC Immunol 2005; 6:13
27. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S. Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 1998; 17:200-6
28. Cha TA, Tom E, Kemble GW, Duke GM, Mocarski ES, Spaete RR. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 1996; 70:78-83
29. Benedict CA, Butrovich KD, Lurain NS, et al. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J Immunol 1999; 162:6967-70
30. Cheung TC, Humphreys IR, Potter KG, et al. Evolutionarily divergent herpesviruses modulate T cell activation by targeting the herpesvirus entry mediator cosignaling pathway. Proc Natl Acad Sci U S A 2005; 102:13218-23
31. Gerna G, Percivalle E, Lilleri D, et al. Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131-128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol 2005; 86:275-84
32. Tomasec P, Wang EC, Davison AJ, et al. Downregulation of natural killer cell-activating ligand CD155 by human cytomegalovirus UL141. Nat Immunol 2005; 6:181-8
33. Wang D, Shenk T. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 2005; 79:10330-8
34. Hahn G, Revello MG, Patrone M, et al. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J Virol 2004; 78:10023-33